Sandbox-ID-Skin and Soft Tissues

# Skin and Soft Tissues

## Acne vulgaris   Return to Top 

## Acne rosacea   Return to Top 

## Anthrax, cutaneous   Return to Top 

## Bacillary angiomatosis   Return to Top 

## Bite wounds   Return to Top 

## Bubonic plague   Return to Top 

## Carbuncle   Return to Top 

## Cat scratch disease   Return to Top 

## Cellulitis   Return to Top 

## Ecthyma   Return to Top 

## Erysipelas   Return to Top 

## Erysipeloid   Return to Top 

## Erythrasma   Return to Top 

## Fournier gangrene   Return to Top 

## Furuncle   Return to Top 

## Gas gangrene   Return to Top 

## Glanders   Return to Top 

## Impetigo   Return to Top 
- Impetigo, bullous and nonbullous
- Causative pathogens
- Staphylococcus aureus
- Streptococcus, -hemolytic
- Impetigo, adult
- Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and -hemolytic streptococci)
- Limited number of lesions
- Preferred regimen: Mupirocin topically bid for 5 days OR Retapamulin topically bid for 5 days
- Numerous lesions or outbreaks of poststreptococcal glomerulonephritis
- Preferred regimen: Dicloxacillin 250 mg PO qid for 7 days OR Amoxicillin-Clavulanate 875/125 mg PO bid for 7 days OR Cephalexin 250 mg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Doxycycline 100 mg PO bid for 7 days OR Clindamycin 300400 mg PO qid for 7 days OR Sulfamethoxazole-Trimethoprim 12 double-strength tablets PO bid for 7 days
- Pathogen-directed antimicrobial therapy
- Streptococcus alone
- Preferred regimen: Penicillin V 250500 mg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Erythromycin 250 mg PO qid for 7 days OR Clindamycin 300400 mg PO qid for 7 days
- Staphylococcus aureus, methicillin-resistant (MRSA)
- Preferred regimen: Doxycycline 100 mg PO bid for 7 days OR Clindamycin 300450 mg PO qid for 7 days OR Sulfamethoxazole-Trimethoprim 12 double-strength tablets PO bid for 7 days
- Impetigo, pediatric
- Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and -hemolytic streptococci)
- Limited number of lesions
- Preferred regimen: Mupirocin topically bid for 5 days OR Retapamulin topically bid for 5 days
- Numerous lesions or outbreaks of poststreptococcal glomerulonephritis
- Preferred regimen: Amoxicillin-Clavulanate 25 mg/kg/day of amoxicillin component PO bid for 7 days OR Cephalexin 2550 mg/kg/day PO tidqid for 7 days
- Alternative regimen (for penicillin-allergic patients): Clindamycin 2530 mg/kg/day PO tid for 7 days OR Sulfamethoxazole-Trimethoprim 812 mg/kg/day PO bid for 7 days
- Pathogen-directed antimicrobial therapy
- Streptococcus alone
- Preferred regimen: Penicillin V 60,000100,000 U/kg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Erythromycin 40 mg/kg/day PO tidqid for 7 days OR Clindamycin 20 mg/kg/day PO tid for 7 days
- Staphylococcus aureus, methicillin-resistant (MRSA)
- Preferred regimen: Clindamycin 2530 mg/kg/day PO tid for 7 days OR Sulfamethoxazole-Trimethoprim 812 mg/kg/day PO bid for 7 days

## Lyme disease, cutaneous   Return to Top 

## Mastitis   Return to Top 

## Necrotizing fasciitis   Return to Top 

## Pilonidal cyst   Return to Top 

## Pyomyositis   Return to Top 

## Seborrheic dermatitis   Return to Top 

## Skin and soft tissue infection in neutropenic fever   Return to Top 

## Skin and soft tissue infection in cellular immunodeficiency   Return to Top 

## Surgical site infection   Return to Top 

## Tularemia   Return to Top 

## Vascular insufficieny ulcer   Return to Top 

## Vibrio infection   Return to Top 

## Wound infection   Return to Top 

## Yaws   Return to Top 
-  Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL;  et al. (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America". Clin Infect Dis. 59 (2): 14759. doi:10.1093/cid/ciu296. PMID 24947530.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link) .mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"\"""\"""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{display:none;font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}